COLUMBUS, Ohio–(BUSINESS WIRE)–Battelle and CMC Pharmaceuticals are advancing work with the United States Department of War to develop improved medical countermeasures intended to protect American warfighters from nerve agent threats. The five-year, $40 million Acetylcholinesterase (AChE) Reactivator Development and Approval Pipeline (ARDAP) Prototype Program was awarded through the Defense Threat Reduction Agency, Joint Science and Technology Office (DTRA-JSTO). The program is focused on adv
